Retension Pharmaceuticals CEO buys 20,800 shares

The option award vests over time: 25% vests on August 14, 2027, and continued service is required on each vesting date.

Rhea-AI Filing Summary

Retension Pharmaceuticals, Inc. chief executive officer and director Eric L. Keller reported a direct purchase of 20,800 common shares at $12 per share on October 13, 2026, and an award of 255,174 stock options.

He also reported the automatic conversion of 9,662 Series A and 31,368 Series B preferred shares into common shares immediately before the issuer’s initial public offering closed, without payment of consideration. The options have an $11.63 exercise price and expire October 13, 2036. Twenty-five percent vest on August 14, 2027, with the remainder vesting in 36 monthly increments thereafter, subject to continued service on each vesting date.

Insider Trade Summary

Net Buyer: 20,800 shares

Net Buy 6 txns

Insider Keller Eric L.

Role CHIEF EXECUTIVE OFFICER

Bought 20,800 shs ($250K)

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F3	255,174	$0.00	$0.00
Conversion	Series A Convertible Preferred Stock F1	9,662	--	--
Conversion	Series B Convertible Preferred Stock F2	31,368	--	--
Purchase	Common Stock	20,800	$12.00	$250K
Conversion	Common Stock F1	9,662	--	--
Conversion	Common Stock F2	31,368	--	--

Holdings After Transaction: Stock Option (right to buy) — 255,174 contracts (Direct); Series A Convertible Preferred Stock — 0 contracts (Direct); Series B Convertible Preferred Stock — 0 contracts (Direct); Common Stock — 464,407 shares (Direct)

Footnotes (3)

1. F1. Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date.
2. F2. Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date.
3. F3. Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. Twenty-five percent of the stock option vests on August 14, 2027, with the remaining stock options vesting in 36 monthly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Key Figures

Common shares purchased: 20,800 shares Purchase price: $12 per share Stock options awarded: 255,174 options +5 more

8 metrics

Common shares purchased 20,800 shares Direct purchase on October 13, 2026

Purchase price $12 per share Direct common stock purchase on October 13, 2026

Stock options awarded 255,174 options Awarded October 13, 2026

Option exercise price $11.63 per share Stock option award

Option expiration date October 13, 2036 Stock option award

Series A preferred shares converted 9,662 shares Each converted into one common share

Series B preferred shares converted 31,368 shares Each converted into one common share

Initial option vesting 25% on August 14, 2027 Remaining options vest in 36 monthly increments thereafter, subject to continued service

Key Terms

Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, 2026 Equity Incentive Plan, initial public offering

4 terms

Series A Convertible Preferred Stock financial

"Each share of Series A Convertible Preferred Stock"

Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.

Series B Convertible Preferred Stock financial

"Each share of Series B Convertible Preferred Stock"

Series B convertible preferred stock is a class of shares sold during a later-stage private financing that combines features of a loan and common stock: it usually pays priority dividends or has a priority claim if the company is sold, and it can be converted into common shares under predefined rules. Investors care because these shares affect ownership stakes and payout order—like having a reserved place in line and a ticket that can turn into regular ownership—so they influence potential returns and dilution for other shareholders.

2026 Equity Incentive Plan financial

"pursuant to the Issuer's 2026 Equity Incentive Plan"

initial public offering financial

"prior to the closing of the Issuer's initial public offering"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RTSN shares did Eric L. Keller purchase and at what price?

Eric L. Keller directly purchased 20,800 common shares at $12 per share on October 13, 2026. No Rule 10b5-1 plan is reported.

What are the terms of Eric L. Keller’s RTSN stock option award?

The award was for 255,174 stock options with an $11.63 exercise price and an October 13, 2036 expiration date. Twenty-five percent vests on August 14, 2027, and the remaining options vest in 36 monthly increments thereafter, subject to continued service on each vesting date.

How did Eric L. Keller’s RTSN preferred shares convert into common stock?

The reported conversions involved 9,662 Series A and 31,368 Series B preferred shares. Each preferred share automatically converted into one common share immediately before the issuer’s initial public offering closed, without payment of consideration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/13/2026 - 08:14 PM EDT Accepted by SEC EDGAR 10/13/2026 - 06:12 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Keller Eric L.

(Last) (First) (Middle)

1104 WEST BROAD STREET

SUITE 1029

(Street)

FALLS CHURCH VIRGINIA 22046

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Retension Pharmaceuticals, Inc. [ RTSN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/13/2026		P		20,800	A	$12	423,377	D
Common Stock	10/13/2026		C		9,662	A	(1)	433,039	D
Common Stock	10/13/2026		C		31,368	A	(2)	464,407	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)(3)	$11.63	10/13/2026		A		255,174		(3)	10/13/2036	Common Stock	255,174	$0	255,174	D
Series A Convertible Preferred Stock	(1)	10/13/2026		C			9,662	(1)	(1)	Common Stock	9,662	(1)	0	D
Series B Convertible Preferred Stock	(2)	10/13/2026		C			31,368	(2)	(2)	Common Stock	31,368	(2)	0	D

Explanation of Responses:

1. Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date.

2. Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date.

3. Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. Twenty-five percent of the stock option vests on August 14, 2027, with the remaining stock options vesting in 36 monthly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.

	/s/ Alex Schwartz, Attorney-in-fact	10/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)